Apixaban versus warfarin in patients with atrial fibrillation.

Granger, Christopher B;Alexander, John H;McMurray, John J V;Lopes, Renato D;Deceuninck, Olivier;et.al.
(2011) New England Journal of Medicine — Vol. 365, n° 11, p. 981-992 (2011)

Files

GrangerCB-NEJM2011.pdf
  • Restricted Access
  • Adobe PDF
  • 745.95 KB
Request a copy

Details

Authors
  • Granger, Christopher B
    Author
  • Alexander, John H
    Author
  • McMurray, John J V
    Author
  • Lopes, Renato D
    Author
  • Deceuninck, OlivierUCLouvain
    Collaborator
Show more
Abstract
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992. https://doi.org/10.1056/NEJMoa1107039 (Original work published 2011)